TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Alteration in width of alveolar bone at implant location
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: VAS scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain overall status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in parenting skills
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in parenting style
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: The Brief Pain Inventory-short form
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cmax for Benazepril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf for Benazepril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t for Benazepril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of oral medicines taken
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptance levels of new infant face mask
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of obesity-hypoventilation syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: response rate of XELOX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and toxicity of RFA
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of LS301 in breast as measured by related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Optimal imaging dose of LS301
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ability of LS301 to predict presence of positive margins around partial mastectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Progressive Disease
Endpoint domain: Mortality/survival
Primary endpoint: Rehospitalization for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Ratio of patients who is applicable to CDAI<150
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Ventilatory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of values of safety laboratory measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FLACC PAIN score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in HbA1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Severity of Alopecia Areata Tool (SALT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in handover quality
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Translation initiation factors expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduced risk for obesity (weight, BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean of the last 7 daily average diabetic peripheral neuropathy (DPN) pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to spontaneous eye opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Rate of in-hospital postoperative pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Laparoscopic suturing competency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tissue Oxygen Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (WHOQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bowel and bladder function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen saturation of retinal vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Oxygen extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Over Baseline Over 12 Hours (AOB0-12) for Test Adhesive 1 vs. No Adhesive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Over Baseline Over 12 Hours (AOB0-12) for Test Adhesive 2 vs. No Adhesive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with vital sign abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rates of Severe Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence Rates of Diabetic Ketoacidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of Boluses Using the Auto Population Feature Resulting in Fewer Readings Less Than 70 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Antibody against liraglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: acquisition rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under the drug concentration-time curve (AUC) from time zero to infinite time (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal voluntary isometric contraction (MVIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of severe acute respiratory syndrome (SARS)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Number of Participants Who Adhered to the Assigned Physical Activity During 8-week Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Physical Activity Questionnaire Score at 3 Months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of Subjects Who Complete Post-randomization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: %AUCex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Scale (HDRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progress to ACLF
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Participants Free of Radiographically Evident Metastases
Endpoint domain: Mortality/survival
Primary endpoint: Five-year Cumulative Incidence of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Five-year Cumulative Incidence of Serious Infectious Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in HFCG Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in HFCG Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in percentage of volume of treated calcifications/ossifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of fluid responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of osteoporotic fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in DIAGNOdent readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinical Response (CR) 100 (CR100)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric Residual Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in A1C Blood Glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-reported sleep hygiene
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Serum Anti-toxin A and Anti-toxin B Antibody Concentrations at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum F2 C-terminal Anti-toxin B Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative Fluid Administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean shelf exam scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perineal rupture grade III-IV
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the insulin detemir concentration curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: survival time of the first filter
Endpoint domain: Mortality/survival
Primary endpoint: Survival time of patients
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of haematological toxicity of BDT
Endpoint domain: Adverse events/effects
Primary endpoint: Hemoglobin level - patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of hospital readmission for heart failure
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Major Adverse Study-Related Events (MASRE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With New or Recurrent Venous Thromboembolism (VTE)
Endpoint domain: Adverse events/effects
Primary endpoint: Resultant value achieved in the assessment scale of urge incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hospitalization rate within 180 days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Cutaneous Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of neutropenia (ANC < 500/uL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Physical Activity Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Measure for Cardiovascular Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oxford Depression Questionnaire (ODQ) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acide linolenic 18:3 n-3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of dysplasia and adenocarcinoma
Endpoint domain: Mortality/survival
Primary endpoint: iPTH measurements with 30% or greater decrease from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PASI score response of ≥75% (PASI 75) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence and metastasis rates
Endpoint domain: Mortality/survival
Primary endpoint: change in serum protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the rate of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Progress in disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PIB PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent days abstinent from alcohol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Liver disease susceptibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in family caregiver psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in caregiving burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in family caregiver quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adverse events of all grades
Endpoint domain: Adverse events/effects
Primary endpoint: whole body glucose metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in spirometry (FEV1 and FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: All-cause Death or Tricuspid Valve Surgery, Heart Failure Hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Quality of Life Improvement (KCCQ Overall Score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Probability of being stressed
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence Rate of First Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overtreatment rate of CT/NG
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of gastrointestinal side effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Angular deviation between planned and actual implant position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in occurrence of intrusive memories of trauma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of patients converted to resection for liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of covert-saccades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of calls to EMS for stroke
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants with treatment-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with treatment-related neurological deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with aortic injury associated with the implantation of the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aortic arch branch vessel patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of imaging diagnosis compared to clinical diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in morning FPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time of first analgesic requirements after extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurodevelopmental disabilities in survivors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intensity of functional dyspepsia symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Length of Stay Reduction
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Frequency of peristaltic waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Altitude of peristaltic waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to achieve complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Domestic Violence Exposure
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients Reporting Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac re-hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ankle and calf diameters measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Legs heaviness evaluation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Perceived leg comfort evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hours of night sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change From Baseline in Hamilton Depression Scale (HAM-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Breastfeeding initiation at hospital discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Patients Who Met the ACR20 Responder Index Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar - Arterial Gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FGF2 biomarker analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WEGF biomarker analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microRNAs analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Progression-free Survival (PFS) at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Change in Inventory of Depressive Symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depression, Anxiety Stress Scale (DASS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Wellbeing Scale (WBS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of women delivering at each gestational week
Endpoint domain: Mortality/survival
Primary endpoint: Patient anxiety before patient education
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient anxiety after patient education
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient anxiety after operation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: radiation exposure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Moderate and Severe Postreperfusion Syndrome (PRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of MG-ADL Responders
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Draize Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Protein levels in obese and type 2 diabetes patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Joint Space Width (JSW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cohen Mansfield Agitation Inventory (CMAI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-excision rate
Endpoint domain: Adverse events/effects
Primary endpoint: symptom and psychosocial factors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: LTX free survival
Endpoint domain: Mortality/survival
Primary endpoint: Urinary Albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With a Grade 3 or Higher AE During the Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Treatment Interruption Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical parameters measured at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OFF-time (total hours of awake time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable Outcome (NIHSS Score of 0-1 and/or mRS of 0-1)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 2-weeks strut coverage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of 30-day hospital readmission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change of 30-day ED visit rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cmax of Tamsulosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Tamsulosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-free Survival at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Rate of conversions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PD severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depth of lesion from skin surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion total hemoglobin per PAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of lesion as measured by US
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes